Open Access Open Badges Nano Express

A Novel Docetaxel-Loaded Poly (ε-Caprolactone)/Pluronic F68 Nanoparticle Overcoming Multidrug Resistance for Breast Cancer Treatment

Lin Mei12*, Yangqing Zhang1, Yi Zheng1, Ge Tian2, Cunxian Song3, Dongye Yang14, Hongli Chen5, Hongfan Sun3, Yan Tian2, Kexin Liu2, Zhen Li2 and Laiqiang Huang1*

Author Affiliations

1 The Shenzhen Key Lab of Gene and Antibody Therapy, Center for Biotech and Bio-Medicine and Division of Life Sciences, Graduate School at Shenzhen, Tsinghua University, L308, Tsinghua Campus, Xili University Town, 518055, Shenzhen, Guangdong, China

2 College of Pharmacy, Dalian Medical University, 116027, Dalian Liaoning, China

3 Institute of Biomedical Engineering, Peking Union Medical College & Chinese Academy of Medical Sciences, The Tianjin Key Laboratory of Biomaterial Research, 300192, Tianjin, China

4 Department of Gastroenterology, Xiangya Second Hospital, Central South University, 410011, Changsha, China

5 Department of Life Science and Technology, Xinxiang Medical University, 453003, Xinxiang, China

For all author emails, please log on.

Nanoscale Research Letters 2009, 4:1530-1539  doi:10.1007/s11671-009-9431-6

Published: 16 September 2009


Multidrug resistance (MDR) in tumor cells is a significant obstacle to the success of chemotherapy in many cancers. The purpose of this research is to test the possibility of docetaxel-loaded poly (ε-caprolactone)/Pluronic F68 (PCL/Pluronic F68) nanoparticles to overcome MDR in docetaxel-resistance human breast cancer cell line. Docetaxel-loaded nanoparticles were prepared by modified solvent displacement method using commercial PCL and self-synthesized PCL/Pluronic F68, respectively. PCL/Pluronic F68 nanoparticles were found to be of spherical shape with a rough and porous surface. The nanoparticles had an average size of around 200 nm with a narrow size distribution. The in vitro drug release profile of both nanoparticle formulations showed a biphasic release pattern. There was an increased level of uptake of PCL/Pluronic F68 nanoparticles in docetaxel-resistance human breast cancer cell line, MCF-7 TAX30, when compared with PCL nanoparticles. The cytotoxicity of PCL nanoparticles was higher than commercial Taxotere®in the MCF-7 TAX30 cell culture, but the differences were not significant (p > 0.05). However, the PCL/Pluronic F68 nanoparticles achieved significantly higher level of cytotoxicity than both of PCL nanoparticles and Taxotere®(p < 0.05), indicating docetaxel-loaded PCL/Pluronic F68 nanoparticles could overcome multidrug resistance in human breast cancer cells and therefore have considerable potential for treatment of breast cancer.

Nanoparticles; MDR; Pluronic F68; Poly (ε-caprolactone); Docetaxel; Breast cancer